Plain-English translation of NCT05648214 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is an early-stage trial testing a new experimental medicine called designed to treat metabolic dysfunction-associated steatotic liver disease (fatty liver disease). The study will enroll healthy adults and people with this liver condition to see how safe the medication is, what side effects it may cause, and how the body processes it. Researchers will also explore whether the medication can reduce the amount of fat in the liver.
Fatty liver disease is becoming more common and currently has limited treatment options. This trial is testing whether this new medication, which works by targeting a specific gene, could help people with this condition reduce liver fat and improve their health.
You likely qualify if…
You likely don't qualify if…
If you are a healthy volunteer, you will receive a single dose or multiple doses of the medication (or placebo) and have your blood drawn at various time points to see how your body processes it. If you have fatty liver disease, you will receive the medication over several months with regular clinic visits, blood tests, and MRI scans to measure changes in liver fat. The study has three parts: Part A involves healthy adults only, while Parts B and C involve people with fatty liver disease who will be followed for longer periods to assess safety and effectiveness.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States